Teligent Cash Flow from Operating Activities 2012-2021 | TLGT
Teligent cash flow from operating activities from 2012 to 2021. Cash flow from operating activities can be defined as a company's cash flows from operations.
|
Teligent Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2020 | $-17 |
| 2019 | $-18 |
| 2018 | $-13 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $-16 |
| 2014 | $-4 |
| 2013 | $-1 |
| 2012 | $-2 |
| 2011 | $-2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |